<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90819">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922726</url>
  </required_header>
  <id_info>
    <org_study_id>RBSY03 - RESPIRE</org_study_id>
    <nct_id>NCT01922726</nct_id>
  </id_info>
  <brief_title>Registry of Sleep Apnea Monitoring and Atrial Fibrillation in Pacemaker Patients (RESPIRE)</brief_title>
  <official_title>Registry of Sleep Apnea Monitoring and Atrial Fibrillation in Pacemaker Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate at 12 Months follow-up the association between
      Atrial Fibrillation (AF) and Sleep Apnea (SA) severity based on data measured and stored in
      REPLY 200 DR pacemaker.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of severe Sleep Apnea (SA) versus non severe SA patients having Atrial Fibrillation (AF) based on data stored in the pacemaker over 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with severe and non severe SA using the RDI measurement</measure>
    <time_frame>6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of severe SA versus non severe SA patients having sub clinical AF based on data stored in the pacemaker</measure>
    <time_frame>6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of severe SA versus non severe SA patients having AF based on data stored in the pacemaker</measure>
    <time_frame>6, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure time spent in AF in severe SA population and in non severe SA population</measure>
    <time_frame>6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of severe SA versus non severe SA patients (using pacemaker index) having AF diagnosed on clinical assesment</measure>
    <time_frame>6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure AF before and after SA treatment</measure>
    <time_frame>6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the RDI variation day after day</measure>
    <time_frame>6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with severe SA according to the patient pacing indication</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and type of Adverse Events as a Measure of Safety</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure SA before and after AF treatment</measure>
    <time_frame>6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients being treated for SA after being included</measure>
    <time_frame>6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1078</enrollment>
  <condition>Bradycardia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient eligible for implantation of a dual-chamber pacemaker (primo-implant, replacement,
        upgrade) according to current available guidelines Patient with REPLY 200 DR implantation
        performed. Patient who provides signed and dated informed consent according to the local
        laws and regulations
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient eligible for implantation of a dual-chamber pacemaker according to current
             available guidelines

          -  Patient with REPLY 200 DR implantation performed

          -  Patient who provides signed and dated informed consent (according to the laws and
             regulations of the country in which the observational study is conducted)

        Exclusion Criteria:

          -  Inability to understand the purpose of the study or refusal to co-operate

          -  Unavailability for routine follow-ups at the implanting centre

          -  Already included in another clinical study that could affect the results of this
             study

          -  Inability or refusal to provide informed consent

          -  Patient is minor (less than 18-years old)

          -  Patient is pregnant

          -  Patient is forfeiture of freedom or under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio MARTI ALMOR, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Del Mar, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerhard Askamp, Study PM</last_name>
    <phone>+31683672934</phone>
    <email>gerhard.askamp@livanova.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 19, 2015</lastchanged_date>
  <firstreceived_date>August 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
